COSCIENS Biopharma Inc T.AEZ

Primary Symbol: T.AEZS

Healthcare Biotechnology

COSCIENS Biopharma Inc., formerly Aeterna Zentaris Inc., is a specialty biopharmaceutical company engaged in the development and commercialization of a diverse portfolio of pharmaceutical and diagnostic products, including those focused on areas of unmet medical need. Its lead product, macimorelin (Macrilen; Ghryvelin), is an oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). The Company is also engaged in the development of therapeutic assets and proprietary extraction technology, which is applied to the production of active ingredients from renewable plant resources used in cosmeceutical products (i.e., oat beta glucan and avenanthramides, which are found in skincare product brands like Aveeno and Burt’s Bees formulations) and being developed as potential nutraceuticals and/or pharmaceuticals.

TSX:AEZS - Post by User

COSCIENS Biopharma Inc

Bullboard Posts

Post by slagheapon Dec 24, 2015 2:21am

152 Views

Post# 24410809

options

FilingDate TransactionDate Insider Name OwnershipType Securities Nature of transaction Volume or Value Price

Dec 23/15 Dec 21/15 Gnther, Eckhard Direct Ownership Options 50 - Grant of options 5,000 $4.58USD

Dec 23/15 Dec 21/15 Teifel, Michael Direct Ownership Options 50 - Grant of options 10,000 $4.58USD

Dec 23/15 Dec 21/15 Dinges, Jude Direct Ownership Options 50 - Grant of options 40,000 $4.58USD

Dec 23/15 Dec 21/15 Theodore, Philip Allen Direct Ownership Options 50 - Grant of options 40,000 $4.58USD

Dec 23/15 Dec 21/15 Sachse, Richard Direct Ownership Options 50 - Grant of options 40,000 $4.58USD

Dec 23/15 Dec 21/15 Dodd, David Alan Direct Ownership Options 50 - Grant of options 85,000 $4.58USD

Bullboard Posts

Three high-conviction small-cap stocks across the risk spectrum